Impact of intraoperative factor concentrates on blood product transfusions during orthotopic liver transplantation

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2017-12, Vol.57 (12), p.3026-3034
• Main Authors: Colavecchia, A. Carmine, Cohen, David A., Harris, Jesse E., Thomas, Jeena M., Lindberg, Scott, Leveque, Christopher, Salazar, Eric
• Format: Article
• Language: English
• Subjects: Bleeding; Blood products; Blood transfusion; Erythrocytes; Exposure; Fibrinogen; Heart; Hemorrhage; Liver; Liver transplantation; Liver transplants; Lung transplantation; Matching; Morbidity; Patients; Population (statistical); Population studies; Prothrombin; Transplantation; Utilization
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.14328

BACKGROUND Major bleeding in orthotopic liver transplantation is associated with significant morbidity and mortality. Limited literature exists regarding comparative effectiveness of prothrombin complex concentrate and fibrinogen concentrate during orthotopic liver transplantation on blood product utilization. STUDY DESIGN AND METHODS This retrospective, single‐institution study evaluated the impact of prothrombin complex concentrate and fibrinogen concentrate on blood product utilization during orthotopic liver transplantation from December 2013 to April 2016. This study included patients age 18 years or older and excluded patients who received simultaneous heart or lung transplantation or did not meet documentation criteria. A propensity score matching technique was used to match patients who were exposed to prothrombin complex concentrate with unexposed patients, at a 2 to 1 ratio, to control for selection bias. RESULTS During this study, 212 patients received orthotopic liver transplantation with 39 prothrombin complex concentrate exposures. The matched study population included 39 patients who were exposed to prothrombin complex concentrate and 78 unexposed patients. Overall, 84.6% of patients who were exposed to prothrombin complex concentrate also received concomitant fibrinogen concentrate, whereas only 2% of patients in the control group received fibrinogen concentrate. After propensity score matching, no other factors that were included in the model differed significantly or had a standardized mean difference of 0.11 or greater. There was no statistical difference in the utilization of red blood cells or fresh frozen plasma for the exposed group versus the unexposed group after matching (mean ± standard deviation: red blood cell units, 12.4 ± 8.0 units vs. 9.7 ± 5.6 units [p = 0.058]; fresh‐frozen plasma units, 10.0 ± 6.3 vs. 12.7 ± 9.7 units [p = 0.119], respectively). CONCLUSION The intraoperative use of prothrombin complex concentrate and fibrinogen concentrate during orthotopic liver transplantation did not reduce intraoperative blood product requirements at a single institution.